Company / Accounts Receivable
Merck & Co. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$11.8B
FY2025
5-year range
$9.2B / $11.8B
FY2021-FY2025
Trend
+14.6%
vs FY2024
Sector context
#5 of 113
Health Care
What the data says
Among 113 Health Care companies, Merck & Co. is in the top 4% for accounts receivable. Accounts Receivable has fluctuated over the past 10 years, ranging from $6.8B in FY2019 to $11.8B in FY2025.
Based on SEC 10-K filings.
$11.8B in FY2025 with a 5-year CAGR of +11.6%. Top quartile in the Health Care sector.
Improved from $10.3B to $11.8B over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +7.6%
- 5-Year CAGR
- +11.6%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 113This company $11.8B Sector average $1.1B
▼
+935.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +11.6%, indicating consistent growth.
- In FY2025, accounts receivable increased 14.6% year-over-year.
- Ranks #5 out of 113 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2019.
Company context
Key Data Points
- Strong profit margin: 29.6%
- Strong return on equity: 36.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.8B | +14.6% |
| FY2024 | $10.3B | -0.7% |
| FY2023 | $10.3B | +9.5% |
| FY2022 | $9.4B | +2.4% |
| FY2021 | $9.2B | +35.7% |
| FY2020 | $6.8B | +0.4% |
| FY2019 | $6.8B | -4.1% |
| FY2018 | $7.1B | +2.9% |
| FY2017 | $6.9B | -2.1% |
| FY2016 | $7.0B | +8.2% |
As of FY2025 · SEC 10-K · Updated Mar 9, 2026